Solutions for LC/MS Bioanalysis of Antibody Drugs

nSMOL (nano-Surface and Molecular Orientation Limited proteolysis) is Shimadzu’s proprietary, innovative technique that enables selective proteolysis of the Fab region of monoclonal antibodies. The nSMOL Antibody BA Kit is a ready-to-use reagent kit that dramatically improves the productivity and robustness of LC/MS mAb bioanalysis. This technique facilitates method development independent of the variety of antibody drugs and achieves a paradigm shift in the bioanalysis of antibody drugs.
Find out more below how Shimadzu can meet your needs of antibody drug bioanalysis.

Bioanalytical Assessment of Cetuximab in Wistar Rat Plasma Using nSMOL and LCMS-8060

Bioanalytical Assessment of Cetuximab in Wistar Rat Plasma Using nSMOL and LCMS-8060

Cetuximab is a human monoclonal antibody (mAb) for the treatment of metastatic colorectal carcinoma, head and neck cancer. Cetuximab was first approved by U.S. FDA in 2014. In this application, we present bioanalysis of Cetuximab in Wister rat plasma using nSMOL reagent kit and LCMS-8060...

 

LC-MS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL
- Part 5 – Instrument comparison of precision and accuracy –

LC-MS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL - Part 5 – Instrument comparison of precision and accuracy –

In this study, we analyzed bevacizumab using the Shimadzu LCMS-8050 and vender products (LC-MS hybrid mass spectrometer) to compare accuracy and sensitivity. For both analyses, nSMOL proteolysis was used for pretreatment. nSMOL proteolysis enables the quantitation of bevacizumab in human plasma with high precision while also fulfilling the guideline criteria for small molecule drug compounds in terms of precision and accuracy in validation…

 

LC-MS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL
- Part 6 - Improvement of Reaction Conditions for Automated Analyses -

LC-MS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL - Part 6 - Improvement of Reaction Conditions for Automated Analyses -

Shimadzu‘s nSMOL technology enables the acquisition of CDR-peptides through the selective proteolysis of the Fab region. Until now, the nSMOL reaction was done while applying shaking agitation at 50 ℃. However, as this article indicates, causing the reaction under static condition can sufficiently satisfy accuracy and sensitivity for the concentration range from approximately 0.1 to 300 ug/Ml…

 

LC-MS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL
- Part 7 - Tocilizumab Analysis -

LC-MS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL  - Part 7 - Tocilizumab Analysis -

Tocilizumab is a humanized monoclonal antibody against the human interleukin-6 (IL-6) receptor and may block the IL-6 signaling. IL-6 was identified in 1980’s and recent studies have shown that it plays a role in inflammatory immune reactions and that it possesses a wide variety of physiological activities…

 

Related Product

nSMOL Antibody BA Kit

nSMOL Antibody BA Kit

The nSMOL Antibody BA Kit is a ready-to-use reagent kit for collecting monoclonal antibodies from blood or other biological samples using immunoglobulin collection resin, and then performing selective proteolysis of the Fab region of these antibodies via trypsin-immobilized nanoparticles.